260 related articles for article (PubMed ID: 32334500)
1. Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome.
Mandpe P; Prabhakar B; Shende P
Curr Drug Metab; 2020; 21(2):79-88. PubMed ID: 32334500
[TBL] [Abstract][Full Text] [Related]
2. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
[TBL] [Abstract][Full Text] [Related]
5. Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).
Rossanese M; Novara G; Challacombe B; Iannetti A; Dasgupta P; Ficarra V
BJU Int; 2015 Jan; 115(1):32-40. PubMed ID: 24602031
[TBL] [Abstract][Full Text] [Related]
6. Drug therapy for an overactive bladder.
Thiagamoorthy G; Cardozo L; Srikrishna S
Womens Health (Lond); 2015 Jul; 11(4):445-8. PubMed ID: 26238677
[No Abstract] [Full Text] [Related]
7. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
[TBL] [Abstract][Full Text] [Related]
8. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.
Chapple CR; Siddiqui E
Expert Rev Clin Pharmacol; 2017 Feb; 10(2):131-151. PubMed ID: 28001447
[TBL] [Abstract][Full Text] [Related]
9. Profile of mirabegron in the treatment of overactive bladder: place in therapy.
Sharaf A; Hashim H
Drug Des Devel Ther; 2017; 11():463-467. PubMed ID: 28255232
[TBL] [Abstract][Full Text] [Related]
10. Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder.
Yamada S; Chimoto J; Shiho M; Okura T; Morikawa K; Wakuda H; Shinozuka K
J Pharmacol Exp Ther; 2021 May; 377(2):201-206. PubMed ID: 33658313
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation.
Rittig S; Baka-Ostrowska M; Tøndel C; Walle JV; Kjaeer B; Passier P; Bosman B; Stroosma O; Tannenbaum S
J Pediatr Urol; 2020 Feb; 16(1):31.e1-31.e10. PubMed ID: 31787582
[TBL] [Abstract][Full Text] [Related]
12. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
[TBL] [Abstract][Full Text] [Related]
13. Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: Interim (1-year) report from a Japanese post-marketing surveillance study.
Kato D; Tabuchi H; Uno S
Low Urin Tract Symptoms; 2019 Jan; 11(1):14-23. PubMed ID: 28762672
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects.
Iitsuka H; van Gelderen M; Katashima M; Takusagawa S; Sawamoto T
Clin Ther; 2015 May; 37(5):1031-44. PubMed ID: 25791612
[TBL] [Abstract][Full Text] [Related]
15. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
Wagg A; Nitti VW; Kelleher C; Castro-Diaz D; Siddiqui E; Berner T
Curr Med Res Opin; 2016; 32(4):621-38. PubMed ID: 26828974
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post-marketing study.
Yoshida M; Nozawa Y; Kato D; Tabuchi H; Kuroishi K
Low Urin Tract Symptoms; 2019 Jan; 11(1):30-38. PubMed ID: 28901041
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
18. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
Kobayashi M; Nukui A; Kamai T
Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
[TBL] [Abstract][Full Text] [Related]
19. Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.
Nozawa Y; Kato D; Tabuchi H; Kuroishi K
Low Urin Tract Symptoms; 2018 May; 10(2):122-130. PubMed ID: 27860325
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E
Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
